Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PCAS Initiates Kilolab In US
PCAS has declared that it is planing to set up a Kilolab in California, US, aimed at small scale synthesis market. By establishing early relationships, the company expects
PCAS has declared that it is planing to set up a Kilolab in California, US, aimed at small scale synthesis market. By establishing early relationships, the company expects
4SC has reported the dosing of the first patient in its phase II trial with 4SC-201 (resminostat), a pan-histone deacetylase (HDAC) inhibitor, as a new potential treatment option
Omnia Biologics (Omnia) and Aparna Biosciences (AparnaBio) has signed a deal for Omnia to provide AparnaBio with process development and production services. Omnia will provide lentiviral vector technical
AstraZeneca Canada has filed a New Drug Submission (NDS) for FluMist (Influenza Vaccine, Live Attenuated Intranasal) with Health Canada. AstraZeneca Canada intends to bring MedImmune’s vaccine technology to
BioNeutral Group, a specialty chemical technology-based Life Science company, has revealed the independent lab test results conducted at Microbiotest of Sterling, Virginia. The results demonstrated that Ygiene Hospital
Saudi International Petrochemical company, Sipchem has started initial operation of its Carbon Monoxide (CO) plant at Sipchem Acetyls complex in Jubail Industrial City. The new CO plant is
Oculus Innovative Sciences has commercialized its Microcyn Skin and Wound Cleanser with preservatives, in both professional and over-the-counter formulations. Reportedly, the professional product is indicated for use by
China Pharma has received approval from the Chinese State Food and Drug Administration (SFDA) for the production of generic – Omeprazole Sodium injections. Omeprazole is indicated for the
Par Pharmaceutical has announced that its licensing partner, Aveva Drug Delivery Systems, has received final approval from FDA for its Abbreviated New Drug Application for a clonidine transdermal
SyntheMed has received approval from the Ministry of Health of the Russian Federation for use of REPEL-CV in all patients who undergo open heart surgery. Reportedly, REPEL-CV is